Donor lymphocyte infusion (DLI) is a key strategy for the treatment of AML relapse after
allogeneic hematopoietic cell transplantation (allo-HCT) and has been used for either …

Background Chimeric antigen receptor (CAR)-T cells have emerged as a breakthrough
treatment for relapse/refractory hematological tumors, showing impressive complete …

Acute myeloid leukemia (AML) is a heterogeneous disease developed from the malignant
expansion of myeloid precursor cells in the bone marrow and peripheral blood. The …

Abstract With the Food and Drug Administration approval of 9 agents for different acute
myeloid leukemia (AML) indications, the prognosis and management of AML is evolving …

Acute myeloid leukemia (AML) is a heterogeneous malignancy affecting myeloid cells in the
bone marrow (BM) but can spread giving rise to impaired hematopoiesis. AML incidence …

The last decade has seen steadfast progress in drug development in acute myeloid
leukemia (AML) which has moved progressively towards genomic-based therapy. With …

Purpose: We evaluated outcomes of unrelated transplantation for primary
refractory/relapsed (ref/rel) acute myeloid leukemia (AML), comparing two cohorts according …

Simple Summary Patients with acute myeloid leukemia (AML) may have a number of
different mutations. Those with mutations in the FLT3 gene have a higher risk of relapse and …

Acute myeloid leukemia (AML) is a molecularly heterogenous hematological malignancy,
with one of the most common mutations being internal tandem duplication (ITD) of the …

Simple Summary Genetically heterogeneous disorder acute myeloid leukemia (AML) is
marked by recurring mutations in FLT3. Current FLT3 inhibitors and other emerging …